First-line ICIs in renal cell carcinoma
Treatment of metastatic renal cell carcinoma (mRCC) has radically changed, switching from interferon alfa (IFN-α) and high-dose interleukin−2 (HD IL−2) to new targeted therapies directed against tumoral neoangiogenesis, the mammalian target of the rapamycin (mTOR) pathway and immune checkpoints. Of...
Сохранить в:
Главные авторы: | , , , , , |
---|---|
Формат: | |
Опубликовано: |
Taylor & Francis Group,
2023-08-01T00:00:00Z.
|
Предметы: | |
Online-ссылка: | Connect to this object online. |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Internet
Connect to this object online.3rd Floor Main Library
Шифр: |
A1234.567 |
---|---|
Копировать 1 | Доступно |